1
|
Shahbazi F, Shojaei L, Farvadi F, Kadivarian S. Antimicrobial safety considerations in critically ill patients: part II: focused on anti-microbial toxicities. Expert Rev Clin Pharmacol 2022; 15:563-573. [PMID: 35734938 DOI: 10.1080/17512433.2022.2093716] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
INTRODUCTION Antibiotic prescription is a challenging issue in critical care settings. Different pharmacokinetic and pharmacodynamic properties, polypharmacy, drug interactions, and high incidence of multidrug-resistant microorganisms in this population can influence the selection, safety, and efficacy of prescribed antibiotics. AREAS COVERED In the current article we searched PubMed, Scopus and Google Scholar for neurotoxicities, hematologic toxicity and fluid stewardship in intensive care units. EXPERT OPINION Critically ill patients who receive antimicrobial agents should be monitored for neurological, hematologic toxicities especially seizure, thrombocytopenia, and clostridioides infections. Other toxicities including QTc prolongation, electrolyte disturbances, liver enzyme elevation, and infusion-related reactions were being considered. Other changes, including fluid overload, hypoalbuminemia, augmented renal clearance, increased cardiac outputs in septic shock, and acute kidney injury, may influence treatment efficiency and patient outcome.
Collapse
Affiliation(s)
- Foroud Shahbazi
- Department of Clinical Pharmacy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Lida Shojaei
- Department of Clinical Pharmacy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
| | - Fakhrossadat Farvadi
- Center for nanotechnology in drug delivery, Shiraz University of Medical Sciences, Shiraz, Iran
| | - Sara Kadivarian
- Department of Clinical Pharmacy, Faculty of Pharmacy, Kermanshah University of Medical Sciences, Kermanshah, Iran
| |
Collapse
|
2
|
Ferreira-Cendon S, Martinez-Carranza R, Fernandez-Nava MJ, Villaoslada-Fuente R, Sanchez-Gomez H, Santa Cruz-Ruiz S, Sanchez-Ledesma M, Batuecas-Caletrio A. Prevention of Severe Vestibular Hypofunction after Systemic Gentamicin. J Clin Med 2022; 11:jcm11030586. [PMID: 35160038 PMCID: PMC8836904 DOI: 10.3390/jcm11030586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2022] [Revised: 01/16/2022] [Accepted: 01/23/2022] [Indexed: 01/25/2023] Open
Abstract
The importance of early evaluation by a neurotologist in patients with infective endocarditis treated with systemic gentamicin and its impact on the patients’ quality of life was evaluated. This is a longitudinal retrospective cohort study of 29 patients who received intravenous gentamicin for the treatment of infective endocarditis. Patients were classified into two groups: group A, before a neurotologist was included in the treatment protocol, and group B, after the inclusion of a neurotologist. The frequency of the different symptoms in each group was measured, and the gain of the vestibulo-ocular reflex (VOR) and its relationship with the presence of oscillopsia. In total, 13 and 16 patients were assigned to groups A and B, respectively. The mean gain of the VOR measured using the video head impulse test in group A was 0.44 in the best side and 0.39 in the worst side. In group B, the mean gain was 0.71 (best side) and 0.64 (worst side) (p < 0.0001). The patients who complained about oscillopsia had a main gain of 0.41 in the best side and 0.35 in the worst side. Evaluation of vestibular function should be included in the infective endocarditis treatment protocol, including the adverse effects of systemic gentamicin.
Collapse
Affiliation(s)
- Sofía Ferreira-Cendon
- Neurotology Unit, ENT Department, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain; (S.F.-C.); (R.M.-C.); (M.J.F.-N.); (R.V.-F.); (H.S.-G.); (S.S.C.-R.)
- Neurotology Unit, ENT Department, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - Ramon Martinez-Carranza
- Neurotology Unit, ENT Department, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain; (S.F.-C.); (R.M.-C.); (M.J.F.-N.); (R.V.-F.); (H.S.-G.); (S.S.C.-R.)
- Neurotology Unit, ENT Department, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - Maria José Fernandez-Nava
- Neurotology Unit, ENT Department, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain; (S.F.-C.); (R.M.-C.); (M.J.F.-N.); (R.V.-F.); (H.S.-G.); (S.S.C.-R.)
- Neurotology Unit, ENT Department, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - Rosana Villaoslada-Fuente
- Neurotology Unit, ENT Department, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain; (S.F.-C.); (R.M.-C.); (M.J.F.-N.); (R.V.-F.); (H.S.-G.); (S.S.C.-R.)
- Neurotology Unit, ENT Department, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - Hortensia Sanchez-Gomez
- Neurotology Unit, ENT Department, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain; (S.F.-C.); (R.M.-C.); (M.J.F.-N.); (R.V.-F.); (H.S.-G.); (S.S.C.-R.)
- Neurotology Unit, ENT Department, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - Santiago Santa Cruz-Ruiz
- Neurotology Unit, ENT Department, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain; (S.F.-C.); (R.M.-C.); (M.J.F.-N.); (R.V.-F.); (H.S.-G.); (S.S.C.-R.)
- Neurotology Unit, ENT Department, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
| | - María Sanchez-Ledesma
- Department of Internal Medicine, Infectious Diseases, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain;
| | - Angel Batuecas-Caletrio
- Neurotology Unit, ENT Department, University Hospital of Salamanca, IBSAL, 37007 Salamanca, Spain; (S.F.-C.); (R.M.-C.); (M.J.F.-N.); (R.V.-F.); (H.S.-G.); (S.S.C.-R.)
- Neurotology Unit, ENT Department, Faculty of Medicine, University of Salamanca, 37007 Salamanca, Spain
- Correspondence: ; Tel.: +34-923-291-430
| |
Collapse
|
3
|
Abstract
OBJECTIVE To review insights gained from a 21-year experience with gentamicin-induced vestibulotoxicity including differences in vestibulotoxicity between single daily dosing (SDD) and multiple daily dosing (MDD) regimens. STUDY DESIGN Retrospective case series. SETTING Tertiary care center. PATIENTS Patients with gentamicin vestibulotoxicity referred to the Hertz Multidisciplinary Neurotology Clinic between January 1993 and September 2014. INTERVENTION None. MAIN OUTCOME MEASURES Spectrum of vestibular dysfunction measured using videonystagmography, vestibular evoked myogenic potentials, video head impulse testing, and magnetic scleral search coil testing. RESULTS Of 53 patients with gentamicin-induced vestibulotoxicity, 24 received SDD and 29 received MDD treatment. The most common indications for treatment were sepsis, endocarditis, and osteomyelitis. Angular acceleration receptor function (semicircular canals) was more commonly affected than linear acceleration receptor function (otolithic organ of the saccule; 100% vs. 62%). A significant proportion of patients (53%) developed vestibulotoxicity in the absence of nephrotoxicity and 40% experienced vestibulotoxicity in a delayed fashion up to 10 days posttreatment cessation (mean 3.9 ± 0.7). Therapeutic monitoring did not necessarily prevent delayed vestibulotoxicity. Nephrotoxicity was less common for SDD compared with MDD (60% vs. 35%, p = 0.01). However, the SDD group experienced vestibulotoxicity at a lower cumulative dose (6.3 vs. 7.0 g, p = 0.04) and shorter duration of therapy (20.7 vs 29.4 d, p = 0.02). CONCLUSIONS Our study further highlights important insights regarding gentamicin-induced vestibulotoxicity. While SDD is associated with decreased risk for nephrotoxicity compared with MDD, it confers a higher risk for vestibulotoxicity.
Collapse
|
4
|
Qian X, He Z, Wang Y, Chen B, Hetrick A, Dai C, Chi F, Li H, Ren D. Hair cell uptake of gentamicin in the developing mouse utricle. J Cell Physiol 2020; 236:5235-5252. [PMID: 33368220 DOI: 10.1002/jcp.30228] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2020] [Revised: 11/27/2020] [Accepted: 12/08/2020] [Indexed: 12/27/2022]
Abstract
Intratympanic injection of gentamicin has proven to be an effective therapy for intractable vestibular dysfunction. However, most studies to date have focused on the cochlea, so little is known about the distribution and uptake of gentamicin by the counterpart of the auditory system, specifically vestibular hair cells (HCs). Here, with a combination of in vivo and in vitro approaches, we used a gentamicin-Texas Red (GTTR) conjugate to investigate the mechanisms of gentamicin vestibulotoxicity in the developing mammalian utricular HCs. In vivo, GTTR fluorescence was concentrated in the apical cytoplasm and the cellular membrane of neonatal utricular HCs, but scarce in the nucleus of HCs and supporting cells. Quantitative analysis showed the GTTR uptake by striolar HCs was significantly higher than that in the extrastriola. In addition, the GTTR fluorescence intensity in the striola was increased gradually from 1 to 8 days, peaking at 8-9 days postnatally. In vitro, utricle explants were incubated with GTTR and candidate uptake conduits, including mechanotransduction (MET) channels and endocytosis in the HC, were inhibited separately. GTTR uptake by HCs could be inhibited by quinine, a blocker of MET channels, under both normal and stressed conditions. Meanwhile, endocytic inhibition only reduced GTTR uptake in the CoCl2 hypoxia model. In sum, the maturation of MET channels mediated uptake of GTTR into vestibular HCs. Under stressed conditions, MET channels play a pronounced role, manifested by channel-dependent stress enhanced GTTR permeation, while endocytosis participates in GTTR entry in a more selective manner.
Collapse
Affiliation(s)
- Xiaoqing Qian
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.,NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, China
| | - Ziyu He
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.,NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, China
| | - Yanmei Wang
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.,NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, China
| | - Binjun Chen
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.,NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, China
| | - Alisa Hetrick
- Research Service, VA Loma Linda Healthcare System, Loma Linda, California, USA
| | - Chunfu Dai
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.,NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, China
| | - Fanglu Chi
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.,NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, China
| | - Hongzhe Li
- Research Service, VA Loma Linda Healthcare System, Loma Linda, California, USA.,Department of Otolaryngology-Head and Neck Surgery, Loma Linda University School of Medicine, Loma Linda, California, USA
| | - Dongdong Ren
- ENT Institute and Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, Shanghai, China.,NHC Key Laboratory of Hearing Medicine (Fudan University), Shanghai, China
| |
Collapse
|
5
|
Fu J, Wu Z, Zhang L. Clinical applications of the naturally occurring or synthetic glycosylated low molecular weight drugs. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2019; 163:487-522. [DOI: 10.1016/bs.pmbts.2019.03.005] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|